Shanghai Pharmaceutical Chairman: Antibiotic business is expected to inject this year

After the reorganization of Shanghai Medicine (601607. SH) The first semi-annual report was released today. The announcement said the company achieved net profit of 766 million yuan in the first half, a year-on-year increase of 67.5% after deducting Lianhua supermarket equity sales.　　According to Shanghai Pharmaceutical Chairman Lu Mingfang revealed that the previous injection of antibiotics business assets to the listed companies is expected to be injected in the second half.　　Net profit of 766 million yuan Shanghai pharmaceutical semi-annual report shows that the main operating indicators of Shanghai medicine exceeded market expectations and achieved the best level of history. The first half of the company to achieve operating income of 18.523 billion yuan, an increase of 21.66%, the realization of the operating profit of 1.128 billion yuan, the total profit of 1.177 billion yuan, attributable to the listed company shareholders net profit of 766 million yuan, compared to the same period of deduction Lianhua supermarket equity sale to obtain a one-time profit after the operating profit 743 million yuan　　, the total profit of 779 million yuan, attributable to the listed company shareholders net profit of 457 million yuan, growth 51.86%, 51.2%, 67.5% respectively; The first half of Shanghai medicine to achieve earnings per share of 0.3859 yuan, the realization of pharmaceutical business activities generated by the net cash flow of 1.005 billion yuan, an increase of 23.17%.　　As of June 30, 2010, Shanghai medical owner's equity is 11.287 billion yuan, after deducting minority shareholder's interest is 8.997 billion yuan, the total assets is 24.725 billion yuan.　　In addition, the latest data from Shanghai Medicine show that in the end of June, the top ten shareholders are investment institutions, and the position than the end of March there is a significant increase in concentration of positions significantly increased, the number of shareholders significantly reduced, only 70179 households, compared to the end of March 130246 households significantly reduced 46%.　　Antibiotic business in the second half or injected Lu Mingfang yesterday afternoon to the "First financial daily" reporter said that the Shanghai pharmaceutical "triple" restructuring plan when the injection of antibiotics business assets will soon be injected into the listed companies, expected to be completed by the end of this year. Data show that last October, the new medicine "triple" Reorganization plan, Shanghai Pharmaceutical Absorption merger of the other 2 shares listed companies, pharmaceutical assets to achieve the overall listing.　　The overall listing, the only one is not injected into the Shanghai medicine of the assets is the pharmaceutical group antibiotics business. At that time, Lu Mingfang explained that the antibiotics business has not yet reached the listing requirements, so it has not been injected into the listed companies, but the restructuring plan promised to be in the next 24 months to achieve the listing of antibiotics business.　　According to Lu Mingfang yesterday, the company is stepping up antibiotic operations into listed companies, the current progress is smooth, the end of the year is expected to be completed. Lu Mingfang said the interim results of Shanghai medicine are an important and good start. "Antibiotic business is a very important business, this part of the assets into the listed companies are also in accordance with the previous plan in the steady, after the injection of the development of listed companies will be more favorable." ”